For example, a new cytotoxic drug, Ailibulin (41), targeted drug CDK4/6 inhibitor, MDM2 inhibitor, immune checkpoint inhibitor PD-1/PD-L1 (42) monoclonal antibody, etc. have been reported to show benefit in the treatment of dedifferentiated liposarcoma. Here, MDM2 is linked to liposarcoma.